RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/17182591http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/17182591http://www.w3.org/2000/01/rdf-schema#comment"Acute allograft rejection is considered to be a predominately type 1 immune mediated response to the donor alloantigen. However, the type 2 immune mediated response has been implicated in multiple fibroproliferative diseases. Based on the fibro-obliterative lesion found during bronchiolitis obliterans syndrome (BOS), we hypothesized that the type 2 immune mediated response is involved in chronic lung allograft rejection. Specifically, whereas acute rejection is, in part, a type 1 immune response, chronic rejection is, in part, a type 2 immune response. We found the type 2 cytokine, IL-13, to be elevated and biologically active in human bronchoalveolar lavage fluid during BOS. Translational studies using a murine model of BOS demonstrated increased expression of IL-13 and its receptors that paralleled fibro-obliteration. In addition, in vivo neutralization of IL-13 reduced airway allograft matrix deposition and murine BOS, by a mechanism that was independent of IL-4. Furthermore, using IL-13Ralpha2(-/-) mice, we found increased fibro-obliteration. Moreover, anti-IL-13 therapy in combination with cyclosporin A had profound effects on reducing murine BOS. This supports the notion that IL-13 biological axis plays an important role during the pathogenesis of BOS independent of the IL-4 biological axis."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.org/dc/terms/identifier"doi:10.4049/jimmunol.178.1.511"xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Nakamura H."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Ross D.J."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Strieter R.M."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Grusby M.J."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Kunkel S.L."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Burdick M.D."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Lukacs N.W."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Lynch J.P."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Gomperts B.N."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Xue Y.Y."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Weigt S."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Ardehali A."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Keane M.P."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Belperio J.A."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Hogaboam C."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Zisman D.A."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/author"Saggar R."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/date"2007"xsd:gYear
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/name"J Immunol"xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/pages"511-519"xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/title"IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome."xsd:string
http://purl.uniprot.org/citations/17182591http://purl.uniprot.org/core/volume"178"xsd:string